Stay connected
LONDON – An organization of scientists has questioned the reliability of knowledge published through Russian epidemiologists about the early clinical trials of its “Sputnik V” coronavirus vaccine, one of which told CNBC that Russia will have to explain its results.
In an open letter to the editor of the medical journal The Lancet, in which the Russian Gamaleya Research Institute on Epidemiology and Microbiology the effects of initial trials of its coronavirus vaccine last Friday, an organization of scientists said the knowledge was incomplete and showed some. “unlikely models. “
They said the effects showed that teams of participants reported the same degrees of antibodies at other times in the study. So far, there are 27 signatories to the letter, basically scientists founded in Europe, but also several in the United States and Asia.
“There are several models of knowledge that appear for the reported experiments,” the open letter says. “Based on undeniable probabilistic evaluations, it is highly unlikely to observe so many preserved knowledge problems among other experiments. “
Scientists also expressed fear of the lack of original numerical knowledge presented in The Lancet, stating that “no definitive conclusions can be drawn about the reliability of the knowledge presented, with respect to the obvious duplications detected. “
“While potentially of great interest, the studies described in the article published through Lancet present several other topics of concern,” said Enrico Bucci, a professor at Temple University in the United States, in another blog post. Bucci also one of the original authors and signatories of the open letter to the editor of The Lancet.
Explaining his considerations and those of his fellow signatories, Bucci told CNBC on Thursday that “as an organization of scientists, we that published knowledge is far from complete. “
“At this point, I want an explanation and we want clarification, the list of signatories wants Array to be clarified . . . The point here (is that there is) lack of knowledge and strange patterns of knowledge. We cannot come to a conclusion about this vaccine without full access to knowledge. “The Gamaleya Institute was not without delay to receive feedback when contacted through CNBC on Thursday. However, before, he rejected the complaint of his vaccine, with Denis Logunov, deputy director of the institute, issuing in which he said that “the published effects are original and accurate and have been reviewed through five critics of The Lancet,” Reuters reported.
Saying that it was not to gain all the knowledge of clinical trials, Bucci compared it to the publication of the effects of early-stage clinical trials of the AstraZeneca vaccine at the University of Oxford. In this case, he said, the test authors provided 128 pages of additional curtains that colleagues can review. “If you compare the two (studies) Array . . . you can see that something is missing from the Russian exam. “
Bucci said the lack of comprehensive knowledge “is a product of the rush to publish vital things,” adding that “there is undue pressure on scientists and doctors around the world to convey what they’ve done before. They’re ready. “
In giving another example of unexplained results, Bucci said the study component gave the impression of showing other immune cells that generate the same responses in an individual organization. “There are two other types of immune cells, CD4 and CD8, and nine out of nine are exact or very similar values for CD4 and CD8 cells. They are absolutely independent cells, how come nine other people have exactly the same amount of CD4 and CD8?”
Bucci said The Lancet had asked the authors of the Russian to address the considerations raised through the signatories.
The Lancet showed CNBC that it “invited the authors of the Study on Russian Vaccines to answer the questions posed in Enrico Bucci’s open letter. We’re still monitoring the stage closely. “
The Sputnik V vaccine gained regulatory approval from Moscow in August, making it the first in the world to get the soft green despite considerations from fitness officials that the vaccine had not yet been tested on a giant scale or its effects Russia has rejected the complaint of its vaccine , saying it’s effective. Last August, Logunov of Gamaleya said another trial of the vaccine would involve 40,000 participants.
Do you have any confidential information? We want to hear from you.
Sign up for loose newsletters and get more CNBC in your inbox
Get it in your inbox and more information about our services.
© 2020 CNBC LLC. All rights are reserved. An NBCUniversal department
Knowledge is a real-time snapshot: data is delayed for at least 15 minutes, global industry and monetary news, inventory prices, knowledge, and market analysis
Data also by